L-Citrulline API Manufacturers & Suppliers

L-Citrulline is used to support arginine production and urea‑cycle function in nutritional and metabolic formulations. It is applied where enhanced nitric oxide–related pathways or improved nitrogen handling are desired. Its use is common in dietary supplementation and investigational studies focused on amino acid metabolism.

L-Citrulline belongs to the following therapeutic categories: Acids, Acyclic, Amino Acids, Amino Acids, Diamino, Amino Acids, Peptides, and Proteins, Dicarboxylic Acids. This positioning helps teams compare alternative APIs, anticipate pharmacology expectations, and align early research priorities.

The primary indications for L-Citrulline: Used for nutritional supplementation, also for treating dietary shortage or imbalance. These use cases frame the target patient populations and help prioritize formulation and safety evaluations.

L-Citrulline is converted to L-arginine by argininosuccinate synthase. L-arginine is in turn responsible for L-Citrulline's therapeutic affects. Many of L-arginine's activities, including its possible anti-atherogenic actions, may be accounted for by its role as the precursor to nitric oxide or NO. NO is produced by all tissues of the body and plays very important roles in the cardiovascular system, immune system and nervous system. NO is formed from L-arginine via the enzyme nitric oxide synthase or synthetase (NOS), and the effects of NO are mainly mediated by 3',5' -cyclic guanylate or cyclic GMP. NO activates the enzyme guanylate cyclase, which catalyzes the synthesis of cyclic GMP from guanosine triphosphate or GTP. Cyclic GMP is converted to guanylic acid via the enzyme cyclic GMP phosphodiesterase. NOS is a heme-containing enzyme with some sequences similar to cytochrome P-450 reductase. Several isoforms of NOS exist, two of which are constitutive and one of which is inducible by immunological stimuli. The constitutive NOS found in the vascular endothelium is designated eNOS and that present in the brain, spinal cord and peripheral nervous system is designated nNOS. The form of NOS induced by immunological or inflammatory stimuli is known as iNOS. iNOS may be expressed constitutively in select tissues such as lung epithelium. All the nitric oxide synthases use NADPH (reduced nicotinamide adenine dinucleotide phosphate) and oxygen (O₂) as cosubstrates, as well as the cofactors FAD (flavin adenine dinucleotide), FMN (flavin mononucleotide), tetrahydrobiopterin and heme. Interestingly, ascorbic acid appears to enhance NOS activity by increasing intracellular tetrahydrobiopterin. eNOS and nNOS synthesize NO in response to an increased concentration of calcium ions or in some cases in response to calcium-independent stimuli, such as shear stress. _In vitro_ studies of NOS indicate that the Km of the enzyme for L-arginine is in the micromolar range. The concentration of L-arginine in endothelial cells, as well as in other cells, and in plasma is in the millimolar range. What this means is that, under physiological conditions, NOS is saturated with its L-arginine substrate. In other words, L-arginine would not be expected to be rate-limiting for the enzyme, and it would not appear that supraphysiological levels of L-arginine which could occur with oral supplementation of the amino acid would make any difference with regard to NO production. The reaction would appear to have reached its maximum level. However, _in vivo_ studies have demonstrated that, under certain conditions, e.g. hypercholesterolemia, L-arginine could enhance endothelial-dependent vasodilation and NO production.

L-Citrulline is generally well tolerated, with gastrointestinal discomfort reported at high oral doses. Because it contributes to nitrogen handling, individuals with impaired urea cycle function may be at greater risk for disturbances in nitrogen balance. Its conversion to arginine and subsequent nitric oxide production has no documented toxicity concerns in the provided context, but product quality and impurity control are important due to variable specifications across markets.

L-Citrulline’s high aqueous solubility and negative logP allow straightforward preparation of oral solutions and solid oral forms without solubilization aids. Its small, stable amino acid structure supports compatibility with intramuscular aqueous injectables with low risk of degradation. Hygroscopicity may affect powder flow and stability, so solid forms typically require moisture‑protective packaging.

L-Citrulline is classified as a small molecule. That classification shapes process design, impurity profiling, and analytical control strategies.

Oral L-Citrulline is generally stable because it is a small, highly water‑soluble amino acid with no known peptide‑related degradation pathways. The main concern is its hygroscopicity, which can lead to moisture uptake and affect powder flow or stability in solid dosage forms. Moisture‑protective packaging is typically needed to maintain product integrity.